Journal of the National Cancer Institute Advance Access originally published online on October 30, 2009
JNCI Journal of the National Cancer Institute 2009 101(22):1536-1537; doi:10.1093/jnci/djp422
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2009.
NEWS |
Search for New Treatments Intensifies for Triple-Negative Breast Cancer
| The first 10% of the full text of this article appears below. |
Many physicians consider triple-negative breast cancer (TNBC) the most difficult type to treat, and some patients think it is a death sentence. This subtype of breast cancer is extremely aggressive, has limited treatment options, and carries a high risk of recurrence and death. Unlike breast cancers that express hormone receptors for estrogen and/or progesterone and overexpress the HER-2/neu protein, TNBC is negative for all three proteins, so it cannot be treated with drugs specifically targeted at them. Although TNBC accounts for only 15% of breast cancer, it causes a disproportionate number of deaths, particularly among young, black, and Hispanic women, and those with BRCA1 and BRCA2 mutations.
But a spate of recent studies has some experts feeling more optimistic. "Triple negative breast
Vaccines
More Targets